Maxim Group covered SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN), upping its target price to $14.00 today
- Updated: November 29, 2016
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) had its stock price target increased to $14.00 by Maxim Group in a report announced 11/28/2016. The bumped up target suggests a potential upside of 0.37% from the company's previous stock price.
Boasting a price of $10.25, SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) traded 0.49% higher on the day. The last closing price is down -8.46% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same period. SCLN has recorded a 50-day average of $9.76 and a two hundred day moving average of $11.20. 0 shares of SciClone Pharmaceuticals, Inc. traded, down from an avg. volume of 375,056
See Chart Below
SciClone Pharmaceuticals, Inc. has a one year low of $7.36 and a one year high of $15.02 with a PE ratio of 14.64 SciClone Pharmaceuticals, Inc.’s market capitalization is currently $0.
Brief Synopsis On SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company's development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.